Bayer posts early clinical data on follow-up to Loxo’s Vitrakvi

Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology. The phase 1 linked the drug to a 45% response rate in a subpopulation of solid tumor patients resistant or intolerant to a prior TRK inhibitor.